Vycor Medical Q2 2026: Going Concern Warning, Material Weakness, Revenue Down 16%
VYCO has more than doubled off its 52-week low of $0.032 on light trading volume (0.1× avg).
Summary
Vycor Medical's Q2 2026 filing discloses a going concern warning, material weakness in internal controls, and a 16% revenue decline, with cash of only $158,907 and a $300,000 debt maturity looming.
Key Events · Earnings and Guidance · VYCO
-
Going Concern Warning
The company states substantial doubt about its ability to continue as a going concern, citing a working capital deficiency of $4,294,543 and related party liabilities of $3,800,538 as of June 30, 2026.
-
Material Weakness in Internal Controls
Management concluded a material weakness exists due to the lack of a functioning audit committee with independent members, resulting in ineffective oversight of internal controls and procedures.
-
Revenue Decline
Q2 2026 revenue fell 16% year-over-year to $418,264, driven by a 17% decline in the Vycor Medical segment, while NovaVision revenue increased 17%.
-
Debt Maturity Risk
A $300,000 term note to EuroAmerican Investment Corp. matures on December 31, 2026, with accrued interest of $592,833. The company is uncertain whether an extension will be available.
Analysis · VYCO · Industrial Applications And Services
Vycor Medical's Q2 2026 10-Q reveals a going concern warning with a working capital deficiency of $4.29 million, a material weakness in internal controls due to a non-functioning audit committee, and a 16% year-over-year revenue decline. The company has only $158,907 in cash and faces a $300,000 note maturity on December 31, 2026 with no assurance of extension. These factors raise substantial doubt about the company's ability to continue operations, making this a critical update for investors.
At the time of this filing, VYCO was trading at $0.07 on OTC in the Industrial Applications And Services sector, with a market capitalization of approximately $2.3M. The 52-week trading range was $0.03 to $0.50. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.